Lixte Biotechnology (LIXT) Institutional Ownership → The Long-Awaited End of America Update (From Stansberry Research) (Ad) Free LIXT Stock Alerts $2.88 0.00 (0.00%) (As of 05/2/2024 ET) Add Compare Share Share OwnershipStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Lixte Biotechnology (NASDAQ:LIXT)CurrentInstitutional OwnershipPercentage5.10%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$18.29KNumber ofInstitutional Sellers(last 12 months)0 Get LIXT Insider Trade Alerts Want to know when executives and insiders are buying or selling Lixte Biotechnology stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LIXT Institutional Buying and Selling by Quarter Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… Lixte Biotechnology Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails6/5/2023EP Wealth Advisors LLC2,211$786K0.0%N/A0.013% 2/9/2023Ethos Financial Group LLC248,084$126K0.0%N/A1.490% 8/12/2022Almanack Investment Partners LLC.248,084$185K0.0%-66.7%1.490% 11/9/2021BlackRock Inc.13,425$28K0.0%+191.9%0.098% 11/4/2021Almanack Investment Partners LLC.806,050$1.68M0.1%-17.9%5.863% 8/16/2021State Street Corp33,600$102K0.0%N/A0.244% 8/16/2021Sabby Management LLC65,511$199K0.0%-17.8%0.477% 8/13/2021Renaissance Technologies LLC50,900$154K0.0%N/A0.370% 8/13/2021Vanguard Group Inc.74,383$225K0.0%N/A0.544% 8/4/2021Almanack Investment Partners LLC.982,046$2.98M0.3%-5.8%7.189% 5/21/2021Citadel Advisors LLC23,813$79K0.0%N/A0.174% 5/18/2021Citadel Advisors LLC23,813$79K0.0%N/A0.174% 5/11/2021Almanack Investment Partners LLC.1,042,105$3.43M0.3%N/A7.698% 2/16/2021Santa Monica Partners LP166,667$528K0.4%N/A1.347% (Data available from 1/1/2016 forward) LIXT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LIXT shares? During the previous two years, the following institutional investors and hedge funds held shares of Lixte Biotechnology shares: EP Wealth Advisors LLC ($786K), and Almanack Investment Partners LLC. ($185K), Ethos Financial Group LLC ($126K).Learn more on LIXT's institutional investors. What percentage of Lixte Biotechnology stock is owned by institutional investors? 5.10% of Lixte Biotechnology stock is owned by institutional investors. Learn more on LIXT's institutional investor holdings. Which institutional investors have been buying Lixte Biotechnology stock? The following institutional investors have purchased Lixte Biotechnology stock in the last 24 months: Ethos Financial Group LLC ($248.08K), and EP Wealth Advisors LLC ($2.21K). How much institutional buying is happening at Lixte Biotechnology? Institutional investors have bought a total of 250,295 shares in the last 24 months. This purchase volume represents approximately $1.28M in transactions. Which Lixte Biotechnology major shareholders have been selling company stock? The following institutional investors have sold Lixte Biotechnology stock in the last 24 months: Almanack Investment Partners LLC. ($496K). How much institutional selling is happening at Lixte Biotechnology? Institutional investors have sold a total of 496,000 shares in the last 24 months. This volume of shares sold represents approximately $3.69M in transactions. Related Companies: PCSA Major Shareholders KA Major Shareholders ENVB Major Shareholders TFFP Major Shareholders ADIL Major Shareholders PULM Major Shareholders CVKD Major Shareholders VCNX Major Shareholders CANF Major Shareholders TRVN Major Shareholders This page (NASDAQ:LIXT) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTruth about Trump you’ve never heardPorter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
